Isomalt

Summary

Isomalt (CHEMBL2104398) is a phase-3 clinical-stage small molecule; indicated across 1 condition including inflammatory bowel disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 344.31 Da · C12H24O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104398
Name	Isomalt
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3034828
ChEBI	CHEBI:192266
Molecular formula	C12H24O11
Molecular weight	344.31
InChIKey	SERLAGPUMNYUCK-BLEZHGCXSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@H]([C@H]([C@@H](C(CO)O)O)O)O)O)O)O)O

IUPAC name: (3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol

ChEBI definition: A glycosyl alditol consisting of α-D-glucopyranose and (2ξ)-D-arabino-hexitol residues joined in sequence by a (1→1) glycosidic bond.

Also known as: BAY I 3930, BAY-I-3930, C-isomaltidex, E-953, Glucosylsorbitol, Hydrogenated isomaltulose, INS NO.953, INS-953, Isomalt, Isomaltitol, Palatinit, ISOMALT

Patent coverage: 5,757 distinct patent families (12,389 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
inflammatory bowel disease	1	MONDO:0005265	EFO:0003767

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).